The U.S. Food and Drug Administration (FDA) has approved Gallium 68 PSMA-11 (Ga 68 PSMA-11) as a positron emission tomography or PET imaging agent for men with prostate cancer. The molecule is the first approved PET imaging agent that detects prostate cancer lesions by targeting the prostate-specific membrane antigen (PSMA) — a protein produced at high levels by prostate cancer cells. It is approved for patients suspected of cancer recurrence, based on elevated blood levels…
You must be logged in to read/download the full post.
The post FDA Approves First PSMA-targeted PET Imaging Agent for Prostate Cancer appeared first on BioNewsFeeds.